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A number of studies have identified cytosolic prostaglandin E2 synthase (cPGES)/p23 as a cytoplasmic
protein capable of metabolism of prostaglandin E2 (PGE2) from the cyclooxygenase metabolite prostaglandin
endoperoxide (PGH2). However, this protein has also been implicated in a number of other pathways, including
stabilization of the glucocorticoid receptor (GR) complex. To define the importance of the functions assigned
to this protein, mice lacking detectible cPGES/p23 expression were generated. cPGES/p23/ pups die during
the perinatal period and display retarded lung development reminiscent of the phenotype of GR-deficient
neonates. Furthermore, GR-sensitive gluconeogenic enzymes are not induced in the prenatal period. However,
unlike GR-deficient embryos, cPGES/p23/ embryos are small and a proliferation defect is observed in
cPGES/p23/ fibroblasts. Analysis of arachidonic acid metabolites in embryonic tissues and primary fibro-
blasts failed to support a function for this protein in PGE2 biosynthesis. Thus, while the growth retardation
of the cPGES/p23/ pups and decreased proliferation of primary fibroblasts identify functions for this protein
in addition to GR stabilization, it is unlikely that these functions include metabolism of PGH2 to PGE2.
Prostaglandin E2 (PGE2) is a lipid mediator involved in a
wide range of normal biological functions as well as patholog-
ical processes such as chronic inflammation. Biosynthesis be-
gins with the metabolism of arachidonic acid into prostaglan-
din endoperoxide (PGH2) by cyclooxygenase enzymes (COX-1
or COX-2). Three terminal synthase enzymes capable of pro-
ducing PGE2 from COX-derived PGH2 in vitro have been
reported. These include microsomal PGE2 synthase 1 (mPGES1),
microsomal PGE2 synthase 2 (mPGES2), and the cytosolic
PGE2 synthase (cPGES) (24, 59, 60). mPGES1 is a member of
the MAPEG (membrane-associated proteins involved in eico-
sanoid and glutathione metabolism) protein superfamily, and
its expression increases rapidly in many cells after exposure to
proinflammatory cytokines and lipopolysaccharide (LPS) (24,
62, 65). Not surprisingly, in vivo studies of mice lacking this
gene indicate that this enzyme is responsible for the increased
levels of PGE2 measured in many inflammatory responses
(62). However, PGE2 production can still be detected in the
mPGES1-deficient animals, supporting the contention that ad-
ditional pathways are present that, at least under some circum-
stances, can produce PGE2. One candidate is mPGES2. Sim-
ilar to mPGES1, mPGES2 is a microsomal protein. However,
as the expression of the gene coding for this protein is not
induced by LPS treatment and increased levels are not ob-
served in inflamed tissues, it has been suggested that this syn-
thase contributes primarily to maintenance of basal PGE2 lev-
els (38).
The third protein capable of in vitro PGE2 production was
termed cPGES, reflecting the fact that, unlike the other two
synthases, this protein was purified from rat brain cytosolic
extracts. Similar to mPGES1, this synthase was shown to have
glutathione-dependent PGE2 synthase activity (60). cPGES is
expressed in many cell lines and in a wide range of tissues.
Similar to mPGES2, expression of the gene is generally not
sensitive to inflammatory stimuli, with one notable exception.
Tanioka et al. demonstrated that LPS treatment increased
levels of cPGES threefold in the brain (60). Cotransfection of
human cPGES cDNA with COX-1, but not with COX-2, re-
sulted in a large increase in PGE2 production (60). These
findings led to the suggestion that in most cells COX-1 collab-
orates with cPGES in basal PGE2 production.
Peptide mapping demonstrated that cPGES was identical to
human p23, a highly conserved protein that functions as a
cochaperone for Hsp90 (25, 55, 60). The Hsp90 chaperone
system has been shown to be critical for the function of a
variety of hormone and growth factor receptors, including glu-
cocorticoid receptor (GR), mineralocorticoid receptor, andro-
gen receptor, epidermal growth factor receptor, and platelet-
derived growth factor receptor (48). Steroid receptors,
particularly GR, are used extensively to model the interactions
of p23 with Hsp90 chaperone system and its client proteins. An
important function of the Hsp90 complex is to facilitate folding
of the hormone binding domain to a conformation capable of
binding substrate. GR forms a heterocomplex with Hsp90,
Hsp70, and p60, which are sufficient to carry out this folding
change. p23 has been reported to increase the stability and
hormone binding activity of the GR/Hsp90 complex (12). p23
binds directly to Hsp90 with bound ATP to stabilize the GR/
Hsp90 complex from inactivation and disassembly.
GR is a ligand-activated transcription factor that mediates
the biological effects of glucocorticoids. Upon steroid binding,
GR translocates into the nucleus, dimerizes, and binds to glu-
cocorticoid response elements (GREs) upstream of specific
target genes. GR has also been shown to have DNA-binding-
independent mechanisms of gene regulation through direct
protein-protein interactions, or tethering, of transcription fac-
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tors, such as AP-1 and NF-B (40). Many of these glucocorti-
coid-regulated genes, such as the epithelial sodium channel
subunit  (ENaC) and the surfactant proteins (SP-A, SP-B,
and SP-C), are important in the final stages of mouse lung
development. These genes are responsible for the production
of lung surfactant, which increases alveolar stability by decreas-
ing surface tension, and the clearance of lung liquid to improve
lung tissue compliance and gas exchange upon birth (33, 70).
Glucocorticoids are also known to promote the differentiation
of alveolar epithelial cells (AECs) and development of termi-
nal alveoli required for the transition to air breathing (30, 56).
A multifunctional role has been proposed for cPGES/p23 as
both a terminal PGE2 synthase and a cochaperone for the
GR/Hsp90 complex. In addition, many other functions linked
to its association with Hsp90 have been assigned to this pro-
tein. To date, the role of cPGES/p23 in these processes has
been primarily characterized in vitro, so the in vivo role of
cPGES/p23 remains unclear. We have generated a mouse line
deficient in cPGES/p23 to better characterize this protein and
elucidate its role in vivo. The cPGES/p23 deficiency causes
perinatal lethality due to improper lung maturation. We dem-
onstrate that cPGES/p23 is required for both DNA-binding-
dependent and -independent GR functions. However, addi-
tional phenotypes of this animal suggest GR-independent
functions for this protein in development. Characterization of
primary embryonic fibroblasts derived from the cPGES/p23-
deficient mice, as well as embryonic tissues, demonstrates that
cPGES/p23 is not required for PGE2 synthesis.
MATERIALS AND METHODS
Experimental animals. All studies were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals
(23a) as well as the Institutional Animal Care and Use Committee guidelines of
the University of North Carolina at Chapel Hill.
Generation of cPGES/p23-deficient mice. A mouse ES cell line (RST271)
containing an insertional mutation in cPGES/p23 was obtained from BayGenomics,
a gene-trapping resource (57). A gene-trap vector, pGTOTMpfs, was used
that contained a splice-acceptor sequence upstream of a reporter gene, -geo (a
fusion of -galactosidase and neomycin phosphotransferase II genes). This vec-
tor was inserted into the first intron of cPGES/p23, creating a fusion transcript
containing sequences from the first exon joined to the -geo marker. 5 rapid
amplification of cDNA ends followed by automated DNA sequencing was used
to determine the identity of the trapped gene as cPGES/p23. Male chimeras
generated from this ES cell line were bred to B6/D2 females to generate mice
heterozygous for the mutated allele. These heterozygotes were intercrossed to
produce mice homozygous for the mutation. Pregnant heterozygous females
were euthanized with CO2, and embryos were removed by cesarean section. The
genotypes of the offspring were determined by Southern blot analysis. A specific
probe was designed 3 of exon 2 and used to screen genomic DNA digested with
PvuII. Insertion of the vector in the first intron results in a reduced fragment size
for the mutant allele compared to the endogenous wild-type allele.
Northern blot analysis. Total RNA was isolated from embryonic day 18.5
(E18.5) embryos with RNA-Bee (Tel-Test, Inc.) according to the manufacturer’s
instructions. Total RNA (20 g) was separated by gel electrophoresis on a 1.2%
agarose/formaldehyde gel and transferred to a nitrocellulose membrane (Immo-
bilon NC; Amersham Biosciences) overnight. Northern blots were hybridized
with a [32P]dCTP (Amersham Biosciences)-labeled cPGES cDNA probe pre-
pared with a random primed labeling kit (Roche Diagnostics). The cPGES
cDNA probe was generated from commercially available expressed sequence tag
clones (Invitrogen Laboratories). Membranes were hybridized with a -actin
cDNA probe to verify similar RNA loading.
Prostanoid measurements in whole embryos and embryo lungs. Tissues were
flash frozen in liquid nitrogen and stored in the 80°C freezer until use. Samples
were pulverized and then homogenized in 1 phosphate-buffered saline (PBS)
with 1 mM EDTA (pH 7.4) and 10 mM indomethacin and sonicated. Lipids were
purified through an Amprep octadecyl C18 mini column (Amersham Bio-
sciences), and prostanoid content was determined by using enzyme immunoassay
kits (Assay Designs) according to the manufacturer’s instructions.
Generation of MEFs. E13.5 embryos were used to generate mouse embryonic
fibroblasts (MEFs). The embryos were washed with sterile PBS, finely minced,
and trypsinized twice for 30 min in a 37°C H2O bath. Tissue debris was discarded,
and the fibroblasts were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum and supplemented with 100 g/ml strep-
tomycin sulfate and 100 units/ml penicillin G sodium at 37°C with 5% CO2.
Prostanoid measurements in MEFs. MEFs were seeded in nickel-well plates
(105 cells/well) and grown to 80% confluence. Fibroblasts were washed and
cultured in 1.5 ml serum-free medium for 1 h. Supernatant was collected, and the
cells were trypsinized and pelleted for total protein determination by the bicin-
choninic acid (BCA) method (Pierce). Enzyme immunoassay kits (Assay De-
signs) were used to determine the amount of PGE2 and thromboxane B2 (TxB2)
in the supernatants. All assays were performed in triplicate, and cells treated with
indomethacin were used as a negative control.
Proliferation assay. Carboxyfluorescein diacetate succinimidyl ester (CFSE
[CellTrace cell proliferation kit; Invitrogen]) was used to stain primary fibro-
blasts to monitor cell proliferation. Primary fibroblasts were plated in a six-well
plate, and 16 h later, the cells were stained with 5 M CFSE according to the
manufacturer’s instructions. Cells were harvested, counted, and analyzed with a
FACScalibur flow cytometer (Becton Dickinson) and CellQuest software at the
indicated time points. The doubling time has been calculated by using the
equation Yt 	 Y(o)  2nt, where Yt 	 number of cells at time t, Y(o) 	 initial
number of cells, and n 	 number of cell cycles/hour.
Light microscopy and histological analysis. Tissues were removed from em-
bryos, fixed overnight in 10% formalin, and embedded in paraffin. Sections of
lung and liver tissues were stained with hematoxylin and eosin for routine
histology. Liver sections were also stained with periodic acid-Schiff stain (PAS)
for glycogen content. Sections were observed using a light microscope (Nikon
FXA).
Transmission electron microscopy. Lungs were dissected from E18.5 embryos
and fixed in 2% paraformaldehyde–2.5% glutaraldehyde in 0.15 M sodium phos-
phate (pH 7.4). Following three rinses with phosphate buffer, the samples were
postfixed for 1 h in 1% osmium tetroxide–1.25% potassium ferrocyanide in
sodium phosphate buffer. The tissues were rinsed in deionized water and dehy-
drated through increasing concentrations of ethanol (30, 50, 75, 100, and 100%
for 10 min each) and put through two changes of propylene oxide (15 min each).
Tissue samples were infiltrated with a 1:1 mixture of propylene oxide-Polybed
812 epoxy resin (1A:2B formulation; Polysciences, Inc., Warrington, PA) for 3 h
followed by an overnight infiltration in 100% resin. The tissue pieces were
embedded in fresh epoxy resin and polymerized for 24 h at 60°C. The blocks were
trimmed, and 1-m sections of the tissue were mounted on glass slides and
stained with 1% toluidine blue O in 1% sodium borate. Representative areas
were selected by light microscopy, and 70-nm ultrathin sections were cut using a
diamond knife. Ultrathin sections were collected on 200 mesh copper grids and
stained with 4% aqueous uranyl acetate for 15 min, followed by Reynolds’ lead
citrate for 7 min. Sections were observed using a LEO EM910 transmission
electron microscope at 80 kV (LEO Electron Microscopy, Thornwood, NY)
and photographed using a Gatan Bioscan digital camera (Gatan, Inc., Pleas-
anton, CA).
Isolation of RNA and quantitative RT-PCR. For quantitative real-time PCR
(RT-PCR), lung tissue was removed from E18.5 embryos and total RNA was
isolated by RNA-Bee (Tel-Test, Inc.) according to the manufacturer’s instruc-
tions. The RNA concentration was determined by A260. RNA was purified using
the RNeasy mini kit (QIAGEN), and 5 g was used to generate cDNA with the
high-capacity cDNA Archive kit (Applied Biosystems). cDNA (2.5 ng) was used
in amplification reactions with Taqman PCR universal mastermix and commer-
cially available primer and probe sets (Applied Biosystems) on an ABI Prism
7900 thermocycler. Expression levels were normalized to an endogenous control,
-actin. Quantification of samples was performed using the comparative cycle
threshold (

CT) method, as described in the Assays-on-Demand Users Manual
(Applied Biosystems, Foster City, CA). Relative gene expression was determined
by the formula x  2

CT. Results were expressed as change (fold) relative to
wild-type expression levels.
Western blot analysis. Total protein was isolated from tissue by homogenizing
frozen tissue in lysis buffer (50 mM HEPES, 0.15 M NaCl, 1.5 mM MgCl2, 1%
Triton X-100, 10% glycerol, 10 g/ml leupeptin, 500 M Na3VO4, 0.1 M phenyl-
methlysulfonyl fluoride, Roche Complete mini protease inhibitor tablet). Homoge-
nates were centrifuged at 14,000 rpm for 5 min at 4°C, and protein content of the
supernatant was measured using the BCA assay (Pierce). A quantity of 75 g of
protein per sample was separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and electrophoretically transferred onto polyvinylidene difluoride
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membranes (Hybond-P; Amersham Biosciences). Membranes were blocked in 5%
nonfat milk in 1 TBST (Tris-buffered saline and 0.05% Tween 20) for 1 h at room
temperature. Immunoblots were probed with primary antibody to GR (Abcam
[ab3579, dilution of 2.5 g/ml, incubated at 4°C overnight]), cPGES/p23 (Cayman
[dilution of 1:500, incubated at room temperature for 1 h), and -actin (Sigma
[dilution of 1:5,000, incubated at room temperature for 1 h]) followed by goat
anti-rabbit or goat anti-mouse secondary antibody (dilutions of 1:5,000 and 1:10,000,
respectively) for 45 min at room temperature. Membranes were incubated with ECL
enhanced chemiluminescence reagent, and signal was detected by autoradiography
after exposure to Hyperfilm (Amersham Biosciences).
For the nuclear localization analysis, 1.5  106 fibroblasts were starved from
serum for 24 h and activated with 10 nM dexamethasone for 0, 30, and 60 min.
Cell pellet was resuspended in 200 l of lysis buffer (Hank’s balanced salt
solution buffer, 1.26 mM calcium, 1 mM magnesium, 0.1% NP-40, 200 nM
phenylmethylsulfonyl fluoride, and Roche Complete mini protease inhibitor
tablet) and kept on ice for 20 min before centrifugation at 700  g for 20 min at
4°C. Nuclear pellet was washed in 200 l lysis buffer, centrifuged at 700  g for
20 min at 4°C, resuspended in protein sample buffer, and processed for Western
blotting. Cytoplasmic supernatant was recentrifuged at 12,000  g for 20 min,
and the supernatant was mixed with 80 l of protein sample buffer and processed
for Western blotting. GR was detected on Western blotting by M20 antibody
(Santa Cruz Biotechnology). The blots were reprobed with antibodies to -tu-
bulin (Sigma) and histone H1 (Santa Cruz Biotechnology).
Transfection assay. Primary fibroblasts were immortalized by transfection with
pSV3-neo (ATCC), a plasmid expressing simian virus 40 large T antigen. Trans-
formed fibroblasts (2  105 cells) were seeded in a six-well plate, and after 24 h,
fibroblasts were transfected with either 3 g of pGRE-luc (Clontech) and 0.05 g of
pCMV (Applied Biosystems) or 3 g of pTAL-luc (Clontech) and 0.05 g of
pCMV using Lipofectamine Plus reagent (Invitrogen) according to the manufac-
turer’s instructions. After transfection, the fibroblasts were incubated with dexa-
methasone (10 nM) for 24 h. Cell lysates were collected and analyzed for luciferase
and -galactosidase expression using the dual-light luciferase/-galactosidase re-
porter gene assay kit (Applied Biosystems). Luciferase activity was normalized to
-galactosidase activity. Negative control values from the transformed fibroblasts
transfected with pTAL-luc were subtracted from the experimental values.
Immunofluorescence staining of transformed MEFs for GR. Coverslips (no. 1;
12-mm circle; thickness range, 0.13 to 0.17 mm [Fisher Scientific, Pittsburgh,
PA]) were coated with 0.1% gelatin. Cells were resuspended in growth medium
at a final concentration of 4  104 cells/ml. Five hundred or 1,000 l of suspen-
sion was applied to a coverslip in a 24-well plate, and the cells were allowed to
adhere for 3 h at 37°C. Cultivation medium was replaced by medium without
serum, and cells were starved for 16 h. Cells were activated by 10 nM dexameth-
asone for 0, 30, and 60 min in medium without serum. Activation was stopped by
ice-cold PBS, and cells were immediately fixed by methanol for 20 min at 20°C
and permeabilized for 1 min by acetone at 20°C. Cells were blocked in blocking
buffer (20% fetal bovine serum, 5% bovine serum albumin, 0.05% gelatin) for 30
min at room temperature and incubated with GR antibody (M-20; Santa Cruz
Biotechnnology Inc., Santa Cruz, CA) diluted 1:150 in TBST buffer (10 mM Tris,
150 mM NaCl, 0.1% Tween) overnight at 4°C. Coverslips were washed three
times in TBST buffer and incubated with fluorescein isothiocyanate-conjugated
antirabbit antibody (Jackson ImmunoResearch, West Grove, PA) diluted 1:100
at room temperature for 1 h. Coverslips were washed three times with TBST
buffer and two times with PBS, dried, mounted on slides (SuperFrost Plus
microscope slides; Fisher Scientific) in mounting solution, and examined with a
Nikon Microphot FXA upright fluorescence microscope (Nikon, Inc., Garden
City, NY) using a 60 objective. ImageJ software (NIH) was used to measure the
mean pixel density in the nucleus.
Statistical analysis. Values are presented as mean  standard error of the
mean and are analyzed by Student’s two-tailed t test (Mann-Whitney or Tukey-
Kramer test for multiple comparisons where indicated). A P value of 0.05 is
considered statistically significant.
RESULTS
Generation of cPGES/p23/ mice. Mouse ES cells with a
gene trap inserted in the first intron of cPGES/p23 were ob-
tained from BayGenomics (57). The gene trap contains splice
acceptors, which direct anomalous splicing of the primary tran-
script, resulting in loss of cPGES/p23 expression. Male chime-
ras generated from this ES cell line were bred to B6/D2 fe-
males to generate mice heterozygous for the mutated allele.
No pups homozygous for the mutant allele were identified at
weaning in litters obtained by intercross of these heterozygous
animals. In contrast, Southern blot analysis of E18.5 embryos
demonstrated the presence of homozygous fetuses at normal
Mendelian frequency (Fig. 1A). Examination and monitoring
of neonates indicated that at least some cPGES/p23/ pups
were alive at birth, but these died shortly thereafter, after
taking several agonal breaths.
To verify that the insertion of the gene trap into intron 1 of the
cPGES/p23 gene resulted in loss of expression, RNA was pre-
pared from cPGES/p23/ and cPGES/p23/ embryos and ex-
pression of cPGES/p23 was determined by Northern blot analysis.
No cPGES/p23 transcript was detected by this method (Fig. 1B).
Similarly, cPGES/p23 could not be detected by Western blot
analysis of protein extracts prepared from the livers and primary
fibroblasts of cPGES/p23/ embryos (Fig. 1C).
Mice lacking COX-2, as well as mice lacking the PGE2 EP4
receptor, die in the perinatal period due to a patent ductus
arteriosus (31, 45). The majority of mice lacking both COX-1
and COX-2 die within 30 min of delivery. We therefore exam-
ined the possibility that cPGES/p23 was required for the PGE2
production essential for maturation of the vessel. Similar to
mice lacking EP4 and COX-2, the ductus failed to close in the
cPGES/p23-deficient mice; however, in contrast to the EP4/
and COX-2/ mice, death of the cPGES/p23-deficient neo-
nates preceded the inflation of the lungs. Although this early
death of the cPGES/p23-deficient mice excludes the assess-
ment of this protein in PGE2 production under various phys-
iological stresses in the mature animal, survival of these em-
bryos to full term allowed us to assess prostanoid production
both in fetal tissues and in cell lines derived from the cPGES/
p23-deficient embryos.
FIG. 1. Generation of cPGES/p23/ mice. (A) Southern blot
analyses of DNA from E18.5 embryos generated by the intercross of
mice heterozygous for the cPGES/p23 mutant allele. (B) Northern blot
analyses of cPGES/p23 mRNA expression in whole E18.5 embryos.
Analysis with a -actin-specific probe verified equal RNA sample load-
ing. (C) Western blot analysis of cPGES/p23 protein expression in
E18.5 liver and MEFs. -Actin expression is shown as a loading con-
trol.
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Analysis of prostaglandin production in cPGES/p23/ em-
bryos. To identify a role for cPGES/p23 in PGE2 production,
we determined PGE2 levels in full-term embryos and E18.5
lungs. Consistent with the PGE2 synthase function assigned to
this protein, PGE2 levels were reduced in the cPGES/p23
/
embryos and embryonic lungs compared to the wild-type tis-
sues. However, a similar decrease in the levels of other COX-
dependent metabolites, TxB2 and prostacyclin, in these tissues
was also observed (Fig. 2A). This finding was not consistent
with loss of expression of a PGE2 synthase, but rather sug-
gested cPGES/p23 might have a pleiotropic function in pros-
taglandin synthesis.
The first step in the synthesis of prostanoids is the release of
arachidonic acid from the plasma membrane by cytosolic phos-
pholipid A2 (cPLA2). A small decrease in the expression of this
enzyme was detected by quantitative RT-PCR of RNA pre-
pared from cPGES/p23/ E18.5 lungs (Fig. 2B). However,
this change did not achieve statistical significance. COX-1 and
COX-2 are essential for the production of PGH2, the common
substrate for all prostanoids. We, therefore, next determined
whether loss of cPGES/p23 resulted in altered expression of
these two enzymes. A 50% reduction in COX-2 and a 30%
reduction in COX-1 transcripts were observed in RNA pre-
pared from the cPGES/p23/ lungs (Fig. 2B).
Increased basal PGE2 and TxB2 levels in MEFs. To further
examine the impact of decreased expression of cPGES/p23 on
prostanoid biosynthesis, we examined the production of PGE2
FIG. 2. cPGES/p23-deficient embryos have a significant decrease
in prostanoid levels and a corresponding decrease in cPLA2 and COX
expression. (A) PGE2, TxB2, and 6-keto-PGF1 (a stable metabolite of
prostacyclin [PGI2]) levels in whole E18.5 embryos and lungs dissected
from E18.5 embryos were measured by enzyme immunoassay. n 	 4.
*, P  0.05, and #, P  0.09 by Student’s t test or P  0.05 by
Mann-Whitney test. (B) Determination of cPLA2, COX-2, and COX-1
expression in total RNA isolated from E18.5 lungs by RT-PCR. Ex-
pression levels were normalized to -actin, an endogenous control, and
the results were expressed as change (fold) relative to wild-type ex-
pression levels. cPGES/p23/ lungs, n 	 7; wild-type lungs, n 	 9. *,
P  0.05; #, P 	 0.06.
FIG. 3. cPGES/p23-deficient primary fibroblasts have a significant
increase in PGE2 and TxB2 levels. MEFs were isolated from cPGES/
p23/ and wild-type embryos. Cells were seeded in 24-well plates and
grown to 80% confluence. After 1 h of incubation in serum-free me-
dium, the supernatant was removed and PGE2 and TxB2 levels in the
supernatant were determined by enzyme immunoassay. The cells in
each well were harvested for total protein determination by the BCA
method. Results are expressed as picograms of prostanoid per micro-
gram of total cell protein per well. Parallel cultures treated with indo-
methacin, which inhibits the enzymatic activities of both COX-1 and
COX-2, served as a negative control in this assay. n 	 6. *, P  0.01.
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in MEFs derived from E13.5 embryos. Since MEFs produce
high levels of PGE2, even in the absence of stimuli (14), we
measured constitutive production of PGE2 in cultures of
cPGES/p23/ and cPGES/p23/ fibroblasts. Equal numbers
of cells were seeded and grown to confluence in 24-well plates.
The cells were cultured in serum-free DMEM for 1 h, and the
PGE2 released into the medium during this time period was
measured. Surprisingly, basal levels of PGE2 were higher in the
cPGES/p23/ fibroblasts than in the wild-type fibroblasts,
which again is not consistent with loss of a PGE2 synthase (Fig.
3). Parallel cultures treated with indomethacin, which inhibits
the enzymatic activity of both COX-1 and COX-2, served as a
negative control in this assay. Compared to these negative
control indomethacin-treated cells, thromboxane levels were
below the detectable limit in the wild-type fibroblasts. How-
ever, thromboxane was easily measured in the supernatant
collected from the cPGES/p23/ cells (Fig. 3); thus, similar to
the in vivo measurements, the change in PGH2 metabolites was
not limited to PGE2.
Growth retardation of the cPGES/p23-deficient embryos.
Our failure to define a role for cPGES/p23 in the direct reg-
ulation of PGE2 levels makes it unlikely that this previously
FIG. 4. Loss of cPGES/p23 results in growth defects in embryos and proliferation defects in the primary embryonic fibroblasts. (A) E15.5 and
E18.5 embryos were removed by cesarean section, and weight and crown-to-rump length were determined. E15.5, cPGES/p23/, n 	 6, and wild
type, n 	 4; E18.5, cPGES/p23/, n 	 6, and wild type, n 	 7. *, P  0.05. (B) Growth curve for cPGES/p23
/ and wild-type primary embryonic
fibroblasts. Equal numbers of cells of each genotype were plated in a six-well plate (three wells per time point for each genotype). At 24-h intervals,
cells were harvested and counted. The supernatant was collected from each well, and the numbers of dead cells present in the supernatant did not
differ between samples. In contrast, a marked reduction in the number of cells present in the wells seeded with cPGES/p23/ cells was observed.
These data are representative of two independent experiments, each performed with two different / and / MEF cultures. (C) Proliferation
assay comparing cPGES/p23/ and wild-type primary fibroblasts. Cells were stained with CFSE and analyzed by flow cytometry 24 and 48 h after
staining. The CFSE intensity at the time of labeling is shown at 0 h. A shift left at 24 and 48 h represents a decrease in CFSE intensity which
corresponds to the rate of proliferation in the population. Shown are the representative results from three independent experiments. Black, wild
type; gray, cPGES/p23/.
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assigned function contributes to the perinatal lethality of these
mice. Further analysis of the mutant animals was carried out to
determine whether the phenotype of the cPGES/p23/ em-
bryos would support other functions assigned to this protein.
Embryos were removed at E15.5 and E18.5, each embryo was
weighed, and the crown-to-rump length was determined. The
weight and length of the E15.5 cPGES/p23-deficient pups
tended to be less than those of the wild-type littermates, but
this difference did not achieve statistical significance with this
small group of animals. However, later in gestation, a signifi-
cant decrease in both the weight and crown-to-rump length of
the mice lacking cPGES/p23 became apparent (Fig. 4A).
To determine whether the smaller size of the cPGES/p23
embryos reflected a role for cPGES/p23 in proliferation, em-
bryonic fibroblast cultures were established from control and
mutant E13.5 embryos. After isolation of these cells and es-
tablishment of the primary cultures, equal numbers of wild-
type and cPGES/p23/ cells were seeded and the growth was
monitored daily. Attached viable cells, as well as the dead cells
present in the culture media, were counted at 24, 48, and 72 h
after plating. As can be seen in Fig. 4B, the growth of the
cPGES/p23-deficient cells lagged behind that of the wild type.
This did not appear to represent a loss of cells due to cell
death, as no difference was observed in the number of dead
cells present in the media. The average doubling time for the
two wild-type primary cell cultures, derived from two different
embryos, was calculated to be 18.3 h, while the average dou-
bling time for two cPGES/p23/ cell cultures was 25.4 h. An
additional two cultures of each genotype were examined, and
the average doubling times were 17.0 h and 33.1 h for the
wild-type and cPGES/p23/ cell cultures, respectively. To
further examine this point, cells were labeled with CFSE. This
dye is retained in the cells but diminishes in intensity with each
round of proliferation. Cells were stained 24 h after plating,
and flow cytometric analysis was performed to determine the
proliferation rate at 24 and 48 h after staining. As shown in Fig.
4C, the cPGES/p23/ fibroblasts were not proliferating as
rapidly as the wild type to produce the next generations at both
24 and 48 h after addition of the dye. Overall, this supports a
role of cPGES/p23 either directly or indirectly in cell cycle
progression of primary fibroblasts.
cPGES/p23/ mice have abnormal lung development. The
small decrease in growth of the cPGES/p23/ pups alone is
unlikely to account for the perinatal lethality of this mutation.
As discussed above, necropsy of the pups indicated minimal
inflation of the cPGES/p23/ lungs after birth. In contrast to
the impact of cPGES/p23 on the overall growth of the pup, the
size of the cPGES/p23/ lungs did not differ from that of
wild-type embryos, and, in fact, measurement of total RNA
content indicated an increase in the cellularity of the lungs at
E18.5 (Fig. 5A). We, therefore, compared the architecture of
the cPGES/p23/ and wild-type lungs at various stages of
FIG. 5. Histological analysis of lung tissue from E15.5 to E18.5 wild-type and cPGES/p23/ embryos by light microscopy. (A) Total RNA was
extracted from E18.5 embryo lungs. Quantitation of RNA revealed a significant increase in the cPGES/p23/ lungs, suggesting hypercellularity.
(B) Lungs were removed from embryos at E15.5, E16.5, E17.5, and E18.5 and fixed overnight in 10% formalin. Lung sections were stained with
hematoxylin-eosin. The cPGES/p23/ lung development appears arrested at the canalicular stage (E16.0 to 17.5). Notable is the failure of the
development of terminal sacs. Original magnification, 10.
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development. Lung development can be divided into four
stages (9). The embryonic stage is marked by the initial branch-
ing of the lung from the primitive foregut and the development
of the bronchopulmonary segments. During the pseudoglan-
dular stage (E12.5 to E16.0), there is further branching of the
duct system generating the conducting portion of the respira-
tory system, including the terminal bronchioles. These early
developmental events were not altered in the mice lacking
cPGES/p23. As shown in Fig. 5B, no apparent differences are
observed between the E15.5 wild-type and cPGES/p23/
lung. During the next two stages of development, the canalic-
ular phase (E16.0 to E17.5) and the saccular/alveolar phase
(E17.5 to postnatal day 5), the terminal bronchioles undergo
further branching to form the respiratory bronchioles. This is
followed by the formation of terminal sacs and thinning of the
stroma that separated these saccules from the developing vas-
cular bed, thus forming the thin diffusible interface between
the airways and the pulmonary circulation required after birth.
It is during the canalicular stage that differences in the devel-
opment of the cPGES/p23/ lungs become apparent. At
E18.5, the cPGES/p23/ lungs still display morphology simi-
lar to the wild-type lungs early in the canalicular stage (Fig.
5B). Terminal sac development appears absent in the cPGES/
p23/ embryos, resulting in a more condensed lung architec-
ture. Thus, the development of the cPGES/p23/ lungs ap-
pears arrested in the canalicular stage (E16.0 to E17.5).
Transmission electron microscopy was used to compare the
epithelial cell profiles as well as other ultrastructural features
of the lungs from cPGES/p23/ and wild-type full-term em-
bryos. In the wild-type embryonic lung, type II AECs, progen-
itors of type I alveolar epithelial cells (type I AECs), can easily
be distinguished within each saccule by their cuboidal shape,
FIG. 6. Abnormal ultrastructure of the distal airway in cPGES/p23/ embryos. Transmission electron microscopy was used to analyze
ultrastructural morphology in E18.5 lung tissue from wild-type (A) and cPGES/p23/ (B) embryos. The electron micrographs demonstrate
squamous type I AECs (black arrowhead) and cuboidal type II AECs containing lamellar bodies (white arrows) and apical microvilli (black arrows)
in the wild-type lung. In contrast, while type II AECs were detected in the cPGES/p23/ lungs, type I AECs could not be identified. s, surfactant.
(C) RT-PCR analysis was used to determine expression of a bronchial epithelial cell marker (NKCC1), a Clara cell-specific marker (TTF-1), type
I AEC markers (aquaporin-5 and T1), and type II AEC markers (DC-LAMP, SP-A, SP-B, and SP-C). Expression levels were normalized to
-actin, an endogenous control; the results are expressed as change (fold) relative to wild-type expression levels. cPGES/p23/ lungs, n 	 7;
wild-type lungs, n 	 9. *, P  0.05.
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apical microvilli, and the presence of the lamellar bodies, struc-
tures essential for the intracellular storage of surfactant. The
saccules are largely lined by type I AECs (Fig. 6A). The thin
cytoplasmic extensions of this cell type reduce the air-capillary
interface. Thus, the differentiation of these cells from their
type II AEC precursors is essential for survival. Marked dif-
ferences are observed in the ultrastructure of the distal lungs
obtained from cPGES/p23/ embryos. Most notably, no type
I AECs were observed in the cPGES/p23/ lungs (Fig. 6B).
Type II AECs could, however, be identified based on their
unique apical microvilli and lamellar bodies. Consistent with
differentiation of this cell type, surfactant can be identified in
the airways of the cPGES/p23/ lung. The distal airway of the
cPGES/p23/ embryos also contains a large number of cuboi-
dal cells which cannot be classified, based on morphological
characteristics. It is likely that these represent precursors of
type II AECs.
To further examine the developmental changes in the
cPGES/p23/ lungs, we prepared RNA from E18.5 embryo
lungs and quantitated the expression of genes which are com-
monly used as cell-specific markers for airway epithelia, type I
AECs, and type II AECs. In the lung, especially in the neonatal
period, the airway epithelia expresses high levels of the Na-
K-2Cl cotransporter (NKCC1) (53). The thyroid transcrip-
tion factor (TTF-1) is expressed in both type II AECs and in
Clara epithelial cells and has been used previously as a specific
marker of lung epithelial cell demarcation (76, 79). No differ-
ence in expression of these two genes was observed between
wild-type and cPGES/p23/ animals, indicating normal prox-
imal-distal epithelial cell patterning (Fig. 6C).
To quantitate the loss of type I AECs, quantitative RT-PCR
was used to compare expression of type I cell-specific markers,
T1 and aquaporin 5, in RNA prepared from wild-type and
E18.5 cPGES/p23/ lungs (72). A dramatic decrease in ex-
pression of T1 and aquaporin 5 was observed in the cPGES/
p23/ lungs, consistent with our failure to identify type I cells
in these lung (Fig. 6C).
Analysis of a type II cell-specific marker, dendritic cell lyso-
somal-associated membrane protein (DC-LAMP) (54),
showed a significant decrease in the cPGES/p23/ lungs (Fig.
6C). Similarly, a dramatic decrease in the expression of sur-
factant genes (SP-A, SP-B, and SP-C) was observed (Fig. 6C).
The remarkable changes in the expression of these genes were
greater than predicted given our ability to identify type II
AECs and surfactant in cPGES/p23-deficient lungs.
Expression of GR-sensitive genes in the cPGES/p23/
lungs. The severe lung phenotype of the cPGES/p23-deficient
mice is similar to the lung phenotype of the GR-deficient mice
(5, 8). We, therefore, next determined whether expression of
GR-sensitive genes was altered in the cPGES/p23/ lungs.
The best studied of these genes are those encoding the surfac-
tants. As described above, we observed a significant decrease
in mRNA levels for these genes in the cPGES/p23/ embryos.
The expression of DC-LAMP has also been shown to be sen-
sitive to glucocorticoids (32). Again, a significant decrease in
the expression of this gene was observed in the mutant lungs.
However, interpretation of these differences is complicated
since these genes are expressed almost exclusively by type II
AECs, and thus the paucity of mRNA may reflect both de-
creased numbers of mature type II AECs and regulation of
these genes by GR. We therefore also examined the expression
of ENaC, whose expression has also been shown to be sensi-
tive to glucocorticoids (53, 68). mRNA levels of ENAC were
analyzed by quantitative RT-PCR, and a significant decrease
in expression was measured in the cPGES/p23/ lungs
(Fig. 7A).
Recently, glucocorticoids have been shown to be important
in regulating the growth factor midkine (MK). From E16.5 to
E17.5, a significant decrease in the expression of the MK gene
was observed in wild-type mice but not embryos lacking GR.
Thus, in these mutant animals, levels at birth are threefold
higher than those in wild-type littermates (27). We reasoned
that if cPGES/p23 is essential for GR function, we would
expect a similar pattern of expression in cPGES/p23/ lungs.
Consistent with this, MK expression was threefold higher in
the cPGES/p23-deficient mice than in the wild-type mice (Fig.
7A). Taken together, the decreased expression of ENAC and
the increased expression of MK indicated that cPGES/p23 is
essential in the regulation of glucocorticoid-sensitive genes in
the mouse lung. To determine whether this loss of GR function
was the result of decreased levels of GR, protein extracts were
prepared from wild-type and cPGES/p23/ fetal lungs. No
significant difference in the level of the steroid receptor was
observed, suggesting that loss of cPGES/p23 primarily altered
the activity of the receptor (Fig. 7B).
cPGES/p23 is necessary for the induction of gluconeogenic
enzymes. The analysis of expression of glucocorticoid-regu-
lated genes in the lung is complicated by the dramatic alter-
ations in the development of this organ in the cPGES/p23/
animals. To further verify the relationship between cPGES/p23
and expression of GR-sensitive transcripts, we examined the
expression of genes required for gluconeogenesis in the liver of
the E18.5 wild-type and cPGES/p23/ embryos. While glu-
FIG. 7. cPGES/p23/ mice have alterations in expression of glu-
cocorticoid-regulated genes in the lung. (A) RT-PCR analysis was used
to determine expression levels of glucocorticoid-regulated genes, in-
cluding ENaC and MK, in total RNA isolated from E18.5 lungs.
Expression levels were normalized to -actin, an endogenous control;
the results are expressed as change (fold) relative to wild-type expres-
sion levels. cPGES/p23/ lungs, n 	 7; wild-type lungs, n 	 9. *, P 
0.05. (B) Western blot analysis of GR expression in E18.5 lungs from
wild-type and cPGES/p23/ embryos demonstrates similar GR pro-
tein levels. -Actin expression verifies equal sample loading.
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coneogenesis in the mouse does not occur until after birth, the
induction of some of the enzymes, including glucose-6-phos-
phatase and serine dehydratase, is observed late in gestation
(2, 18). The final step of both gluconeogenic and glycogenolytic
pathways is carried out by glucose-6-phosphatase, and the con-
tribution of glucocorticoids to the regulation of the expression
of this gene has been noted (66). The promoter contains a
number of GREs, and the binding of GR together with other
accessory factors forms the glucocorticoid response unit, which
regulates gene expression. Levels of expression of both glu-
cose-6-phosphatase and serine dehydratase were significantly
decreased in the cPGES/p23/ livers (Fig. 8A). A similar
decrease has been reported for these genes in GR-deficient
mice (7). To further examine the role of cPGES/p23 in matu-
ration of the liver, we examined the accumulation of glycogen,
which normally begins to accumulate late in gestation. Previ-
ous studies have suggested a role for glucocorticoids in this
induction (67). The cPGES/p23-deficient mice have abnormal
liver morphology compared to the wild-type mice at E17.5
(Fig. 8B and C). Analysis of the livers by PAS staining con-
firmed the failure of glycogen to accumulate in the cPGES/
p23/ livers (Fig. 8D and E).
Delayed maturation of the skin in cPGES/p23/ embryos.
Upon external examination, the skin of the cPGES/p23/
mice appeared more translucent than that of their littermates.
Histological examination of the dorsal stratified epithelium
from one pair of E17.5 wild-type and cPGES/p23/ embryos
and three pairs of genetically matched E18.5 embryos showed
that loss of cPGES/p23 had indeed altered the development of
this organ. As expected, all of the structures of the skin were
apparent on examination of the sections obtained from the
E17.5 wild-type fetus (Fig. 9). A single basal layer of prolifer-
ating cells and the suprabasal layers of terminally differentiat-
ing cells transitioning as they move towards the surface of the
skin were observed. Transcriptionally active spinous and gran-
ular cells, as well as several layers of stratum corneum, con-
sisting of metabolically inert enucleated cells, are apparent at
this embryonic stage. Similar to the wild-type pups, the basal
epithelial cells were easily identified in the cPGES/p23/ an-
imals. A well-defined stratum spinosum was also observed.
However, remarkable differences were noted in the terminal
differentiation of the kerotinocytes. A well-defined stratum
granulosum, characterized by darkly stained keratohyaline
granules, was not present in the cPGES/p23/ skin, although
a few cells with some keratohyalin granules could be identified.
A dramatic deficit in the stratum corneum was also observed.
FIG. 8. cPGES/p23/ mice display abnormal liver morphology
and have alterations in expression of glucocorticoid-regulated genes in
the liver. (A) RT-PCR analysis was used to determine expression levels
of gluconeogenic enzymes, glucose-6-phosphatase (G6pc) and serine
dehydratase (Sds), in total RNA isolated from E18.5 livers. Expression
levels were normalized to -actin, an endogenous control; the results
are expressed as change (fold) relative to wild-type expression levels.
n 	 5. *, P  0.01. (B to E) Livers were removed from embryos at E17.5
and fixed overnight in 10% formalin. Liver sections from wild-type
(B) and cPGES/p23/ (C) embryos were stained with hematoxylin
and eosin for routine histological examination. Glycogen content in the
liver was assessed by PAS staining. Note the intense staining in the
wild-type liver (D) compared to the cPGES/p23/ liver (E). Repre-
sentative results for four embryo livers analyzed for each genotype are
shown. Original magnification, 10.
FIG. 9. Delayed maturation of the skin in cPGES/p23/ embryos.
Aberrations in differentiation and formation of the cornified envelope
in cPGES/p23/ stratified epithelia are shown. Skin from wild-type
and cPGES/p23/ E17.5 and E18.5 fetuses was fixed in formalin and
embedded in paraffin, and sections were cut (5 m) and stained with
hematoxylin and eosin. Sections correspond to the dorsal skin above
the scapular region of the embryo. SC, stratum corneum; GR, granular
layer; KG, keratohyaline granules; SP, suprabasal layer; BL, basal
layer; DE, dermis.
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By E18.5, the stratum granulosum was more apparent in the
mutant fetuses, although the development of this layer and the
degree of granulation varied between the mutant pups. How-
ever, in all three animals, the lamellar organization of the
granulocytic layer, the flattening of the cells, and the discarding
of the nucleus had not progressed to the same degree as in the
skin of the control animals. In fact, in many instances, numer-
ous nucleated cells with some keratohyalin granules were
present at the epithelial surface. In all of the cPGES/p23 mu-
tant animals, deficiencies in the development of the stratum
corneum were apparent.
Loss of GR transactivation and tethering mechanisms in
cPGES/p23/ fibroblasts. As normal levels of GR protein
were measured in the cPGES/p23/ fetal tissue, we next ex-
amined directly the ability of these receptors to activate gene
transcription in cells lacking cPGES/p23. Transformed embry-
onic fibroblasts were transiently transfected with pGRE-luc, a
reporter plasmid with three GRE enhancer elements. Binding
of ligand-bound GR to the GREs drives luciferase expression.
The fibroblasts were cotransfected with pCMV, and -galac-
tosidase expression was used to normalize for transfection ef-
ficiency. pTAL-luc, a reporter plasmid with no GRE enhancer
elements, was independently transfected as a negative control,
and these baseline expression values were subtracted from the
experimental values. Upon incubation with dexamethasone, a
synthetic glucocorticoid, the wild-type fibroblasts had a signif-
icant increase in luciferase expression. The cPGES/p23-defi-
cient fibroblasts had significantly lower luciferase expression
compared to the wild type, suggesting that loss of cPGES/p23
reduces GR transactivation (Fig. 10A).
GR has been shown to inhibit gene transcription through
direct protein-protein interaction, or tethering, with transcrip-
tion factors, such as AP-1. This interaction was first established
for the AP-1-regulated gene coding for collagenase-3 (47).
Relative expression of collagenase-3 was determined after ac-
tivating AP-1 with phorbol 12-myristate 13-acetate (PMA).
The cPGES/p23/ fibroblasts had a similar induction of col-
lagenase-3 compared to the wild-type fibroblasts, suggesting
that the ability of AP-1 to induce gene transcription is not
affected by loss of cPGES/p23. Wild-type fibroblasts treated
with dexamethasone and PMA had a significant reduction in
collagenase-3 expression (Fig. 10B). However, the AP-1-in-
duced expression of collagenase-3 in the cPGES/p23/ fibro-
blasts was not inhibited upon treatment with dexamethasone,
suggesting that loss of cPGES/p23 reduces the ability of GR to
negatively regulate transcription factors such as AP-1.
Defective nuclear translocation of GR in cPGES/p23/ fi-
broblasts. To determine the mechanism for the reduction in
GR transactivation and tethering in the cPGES/p23/ fibro-
blasts, we investigated the ability of GR to translocate to the
nucleus after dexamethasone stimulation. Using immunofluo-
rescent staining, the wild-type fibroblasts showed an increase in
GR in the nucleus after 30 and 60 min of dexamethasone
stimulation (Fig. 11A). cPGES/p23/ fibroblasts showed no
increase in GR in the nucleus after 30 and 60 min of dexa-
methasone stimulation. The nuclear localization of GR was
quantitated by measuring mean pixel density of the nucleus. A
slight increase in GR in the nucleus was measured at 60 min of
dexamethasone stimulation in the cPGES/p23/ fibroblasts;
however, only the wild-type measurements taken at 30 and 60
min of dexamethasone stimulation had a statistically significant
increase in pixel density in the nucleus compared to the non-
stimulated cells.
To further verify the translocation defect, Western blot anal-
FIG. 10. Loss of cPGES/p23 results in defective GR transcriptional
activation and protein-protein tethering mechanisms. (A) Trans-
formed fibroblasts were transfected with the reporters pGRE-luc or
pTAL-luc (negative control) and pCMV- to normalize for transfec-
tion efficiency. The transfected fibroblasts were incubated in the pres-
ence or absence of dexamethasone (Dex [10 nM]) for 24 h. Luciferase
expression and -galactosidase expression were measured in the cell
lysates. The luciferase values were normalized to the -galactosidase
values, and the values obtained from the fibroblasts transfected with
the negative control (pTAL-luc) were subtracted from the values ob-
tained from the fibroblasts transfected with pGRE-luc (three repli-
cates for each treatment and genotype). As expected, dexamethasone
treatment resulted in a significant increase in luciferase expression in
the wild-type fibroblasts. This induction was significantly attenuated in
the fibroblasts lacking cPGES/p23. *, P  0.01. These data are repre-
sentative of three independent experiments performed with two dif-
ferent cell cultures per genotype. (B) Treatment of embryonic fibro-
blasts with PMA (107 M for 6 h), which induces transcription of genes
via AP-1, increased expression of collagenase-3 in both wild-type and
cPGES/p23/ cultures. However, subsequent treatment with dexa-
methasone (106 M for 6 h.) and PMA disrupts induction of this gene
in wild-type but not in the cPGES/p23/ fibroblasts. RT-PCR analysis
was used to determine expression levels of collagenase-3 in total RNA
isolated from the treated fibroblasts. Expression levels were normal-
ized to -actin, an endogenous control; the results are expressed as
change (fold) relative to untreated controls. The data are representa-
tive of two independent experiments with different MEF cultures. n 	
3. *, P  0.05 compared to controls, and #, P  0.05, compared to all
groups by the Tukey-Kramer test for multiple comparisons.
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ysis was performed on nuclear and cytosolic extracts from the
fibroblasts after stimulation with dexamethasone. Similar to
the immunofluorescence, the wild-type fibroblasts had an in-
crease of GR in the nucleus and a decrease of GR in the
cytosol at both 30 and 60 min of dexamethasone treatment.
The cPGES/p23/ fibroblasts had no change in GR in either
the nuclear or the cytosolic fraction (Fig. 11B).
DISCUSSION
We have shown that cPGES/p23 is essential for progression
of lung development from the early to the late canalicular stage
and that pups lacking cPGES/p23 die in the perinatal period as
a result of neonatal respiratory insufficiency. Loss of cPGES/
p23 results in delayed maturation of the skin. cPGES/p23/
pups also fail to induce high levels of gluconeogenic enzymes in
the prenatal period. These phenotypes are consistent with the
proposed function of cPGES/p23 as an Hsp90 cochaperone
essential for stabilization of GR. However, the cPGES/p23/
embryos are smaller in size, and primary cultures of embryonic
fibroblast show decreased proliferation. As these phenotypes
are not observed in the GR-deficient mice, they likely define
cPGES/p23 functions that are independent of GR. Evaluation
of prostaglandin production in the cPGES/p23/ embryos
and in the embryo-derived primary fibroblasts does not sup-
port a direct role for cPGES/p23 in PGE2 synthesis.
We noted differences in the terminal differentiation of the
skin of the cPGES/p23/ pups. In all mice, a severe deficiency
in the cornification of the epithelium was noted at both 17.5
and 18.5 days of gestation. However, at 17.5 days, the skin of
the cPGES/p23/ mice was also deficient in granulocytes,
while this stratum was easily identified in wild-type mice. In-
terestingly, previous studies have shown that injection of glu-
cocorticoids accelerates the functional, morphological, and
lipid biochemical maturation of the permeability barrier of the
skin (1). Later studies of the glucocorticoid-deficient animals
supported the role of this hormone in the differentiation of this
organ (20). Similar to the cPGES/p23/ mice, differences
between the wild-type and mutant animals were more pro-
nounced earlier in development. At E17.5, neither a well-
defined granular layer nor a stratum corneum was evident by
light microscopy in the glucocorticoid-deficient fetuses; how-
ever, these deficits diminished later in gestation. Taken to-
gether, this suggests that the alterations in differentiation of
the skin of the cPGES/p23/ mice are likely the consequence
of loss of GR function.
Morphologically the lungs of the cPGES/p23 full-term em-
bryos resemble those of the early canalicular stage of develop-
ment (E16.5). Most notable is the absence of the terminal
saccules characteristic of the full-term embryo. Examination of
the ultrastructure of the lung and analysis of the expression of
genes specific to distinct populations of airway epithelia indi-
cate normal development of the airways, likely attenuated dif-
FIG. 11. Defective nuclear translocation of GR in cPGES/p23/ fibroblasts. (A) Immunofluorescent staining of transformed fibroblasts for
GR after treatment with dexamethasone demonstrates defective translocation in the cPGES/p23/ fibroblasts. Fibroblasts were treated with
dexamethasone (10 nM) for 0, 30, and 60 min in serum-free medium. Software (ImageJ, NIH) was used to determine the mean pixel density of
the nucleus of representative cells in each culture. n 	 12. *, P  0.05 compared to all other groups by the Tukey-Kramer test for multiple
comparisons. (B) Western blot analysis demonstrates increases in GR in the nucleus and decreases in GR in the cytoplasm after dexamethasone
stimulation (10 nM) for 0, 30, and 60 min in the wild-type fibroblasts. No alterations in GR localization were observed in the cPGES/p23/
fibroblasts after stimulation. Sample loading was verified by expression of -tubulin for the cytoplasmic fraction and histone H1 for the nuclear
fraction. Change was determined by densitometric analysis and normalized to the loading controls.
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ferentiation and/or maturation of type II AECs, and little to no
differentiation of type I AECs from type II precursors. This
phenotype is very similar to that described for GR-deficient
mice. A GR hypomorphic (GRhypo) mouse line with extremely
low levels of GR activity was generated from ES cells in which
the neomycin marker gene was inserted into exon 2 by homol-
ogous recombination (8, 63). While 10% of theses hypomorphs
survive on a mixed genetic background, the coisogenic 129
mice die of respiratory insufficiency in the immediate perinatal
period. Similar to the cPGES/p23/ pups, the lungs of these
pups failed to complete the final stages of maturation, and
their architecture was comparable to that of an E16.5 embryo.
However, unlike the cPGES/p23/ embryonic lung, some
type I AECs were identified in the GRhypo lungs. Two possible
explanations for these differences noted in the differentiation
of the lungs and survival of the GR and cPGES/p23/ mice
are possible. First, this difference may reflect a GR-indepen-
dent cPGES/p23 function in lung development. cPGES/p23
may play a role in stabilizing other Hsp90 clients, such as the
retinoic acid receptor and the estrogen receptor, and many of
these have documented roles in lung development (21, 28, 46,
74). An alternate possibility is that analysis of the GRhypo mice
may reflect residual activity of the GR in these animals com-
pared to the cPGES/p23/ animals. Mice carrying a deletion
of the second or third exon have a more severe phenotype, with
no animals surviving the perinatal period (GRnull); however, a
detailed description of the lung phenotype, as in the GRhypo
mice, has not been described for these mice (5, 63). Final
determination of whether GR-independent cPGES/p23 path-
ways contribute to lung development will require the direct
comparison of congenic GRnull animals and cPGES/p23/
animals under identical breeding and experimental conditions.
However, the remarkable similarities in the phenotype of the
GRhypo and cPGES/p23/ animals are consistent with the
hypothesis that cPGES/p23 is essential for GR actions during
lung development and that the failure of the cPGES/p23/
lungs to mature reflects primarily the loss of this function of
cPGES/p23.
The GR-regulated pathways critical for lung development
have not been identified. Interestingly, a recent study showed
that GR-deficient mice fail to downregulate the expression of
MK, a heparin-binding growth/differentiation factor, which
plays a role in mesenchyme-epithelium interactions during or-
ganogenesis (26, 27, 35). The expression pattern of MK during
lung development is complex, but expression is dramatically
reduced during sacculation of the lung at day 17 of gestation.
It has been suggested that the decrease in expression of MK
signals the lung to initiate maturation, including the thinning of
the mesenchyme critical to this stage of development (36). The
high levels of MK in the lungs of E18.5 GR-deficient embryos
are also observed in the cPGES/p23-deficient embryos. This
continued expression of MK in the cPGES/p23/ embryos
supports the hypothesis that the failure to observe normal
transition from the canalicular stage to the saccular stage of
lung development is secondary to the loss of GR activity in the
cPGES/p23/ embryos.
The GR modulates gene expression through both DNA-
binding-dependent and -independent mechanisms. The rela-
tive importance of these two pathways in development has
been determined by generation of mice expressing a mutant
GR (GRdim) (52). This mutation prevents dimerization of the
receptor, binding of the receptor to GRE sites in promoters,
and transactivation of genes. Study of these mice showed that
lung maturation requires DNA-binding-independent regula-
tory functions of GR since GRdim mice survive into adulthood
and have no severe respiratory defects. The cPGES/p23/
mice die at birth, with a phenotype similar to that of the
GRhypo mice, indicating that cPGES/p23 is important in reg-
ulating the GR in its DNA-binding-independent processes. In
contrast, similar to the GR-deficient mice, gluconeogenic en-
zymes are not induced in the postnatal period in GRdim mice,
demonstrating that expression of these genes is dependent on
DNA binding and transactivation (40). The loss of expression
of glucose-6-phosphatase and serine dehydratase in the livers
from full-term cPGES/p23/ pups indicates that cPGES/p23
is essential for the prenatal activation of enzymes involved in
gluconeogenesis. Again, the most likely interpretation of this
phenotype is that cPGES/p23 is required for the stabilization
of the GR conformation required for ligand binding, subse-
quent nuclear translocation, and transactivation. Consistent
with this, we have shown that the glucocorticoid dexametha-
sone failed to induce GRE-dependent expression of reporter
genes in fibroblast lines established from the cPGES/p23-de-
ficient mice. Our studies also indicate that cPGES/p23 is es-
sential for the regulation of AP-1 by GR, a function that is not
lost in the GRdim mice and thus is a DNA-binding-indepen-
dent function. Furthermore, we have demonstrated that the
loss of both DNA-binding-dependent and -independent mech-
anisms is due to the requirement of cPGES/p23 for the trans-
location of GR to the nucleus.
The cPGES/p23/ pups are approximately 10% smaller in
size than wild-type pups. No similar defect has been reported
for GR-deficient pups—neither the GRhypo nor the GRnull
lines—suggesting this growth retardation is not the result of
decreased GR activity (5, 8). Primary fibroblasts derived from
the cPGES/p23/ embryos have a decreased rate of prolifer-
ation. Again, a similar defect has not been reported for the
GR-deficient primary fibroblasts. In fact, addition of glucocor-
ticoids to fibroblast cultures has been shown to inhibit prolif-
eration (50, 71). cPGES/p23 together with Hsp90 has been
implicated in a number of pathways which, if dysfunctional,
could alter growth, cell cycle transition, and senescence of cells
(3, 34, 39, 49). For example, the Saccharomyces cerevisiae ho-
mologue of p23, Sba1, and Wos2, the Schizosaccharomyces
pombe homologue, together with the corresponding Hsp90
analogues have been shown to regulate Cdc2, a protein kinase
involved in mitotic control (37). A possible role for cPGES/p23
and Hsp90 in the function of telomerase has also been re-
ported (22). However, it is unlikely that dysfunction of this
complex would manifest itself in the first generation of the
cPGES/p23/ pups. Mouse chromosomes possess much
longer telomeres than human cells, and several generations of
breeding are required before loss of telomerase activity results
in altered growth of mice (6). Additional studies will be re-
quired to fully characterize the role of cPGES/p23 in growth
and proliferation.
cPGES/p23 was independently identified as a cytosolic pro-
tein with glutathione-dependent PGE2 synthase activity. The
identification was based not only on the activity of protein
purified from cellular extracts but also on the increase in PGE2
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production by cells cotransfected with a cDNA encoding this
protein and COX-1 (60). This led to the hypothesis that the
cPGES/COX1 pathway was responsible for the production of
PGE2 detected in mice and cell lines lacking mPGES1 (62).
Analysis of the cPGES/p23/ mice fails to support the hy-
pothesis that cPGES/p23 is a bona fide PGE2 synthase. While
loss of cPGES/p23 altered PGE2 production, a corresponding
alteration in the production of other COX-dependent prostan-
oids suggests a more complex and indirect role for cPGES/p23
in this pathway.
Our demonstration that cPGES/p23 is essential for the non-
DNA-binding actions of GR and extensive studies document-
ing a role for GR in regulation of the arachidonic acid pathway
provides an explanation for our results as well as the assign-
ment of a synthase function to this protein. A number of
negative regulatory targets for GR in the arachidonic acid
pathway have been identified, including lipocortin 1 and p11,
proteins capable of modifying the release of arachidonic acid
from membrane phospholipids (11, 77). The primary enzyme
responsible for the release of arachadonic acid from the mem-
brane for metabolism by the prostanoid pathway is cPLA2 (4,
17). Glucocorticoids have been shown to inhibit the expression
and activity of this protein during inflammatory responses (13,
23, 42). Glucocorticoids have also been shown to reduce
COX-2 activity in cells by decreasing COX-2 transcription via
tethering of transcription factors, such as NF-B, essential for
induction of this gene during inflammation (40–42, 51). Fur-
thermore, posttranscriptional regulation and translational reg-
ulation of COX-2 activity have been reported (29, 43, 44).
Consistent with our studies of primary embryonic fibroblasts,
decreased GR activity secondary to loss of cPGES/p23 would
result in loss of this inhibitory pathway, resulting in an increase
in PGE2 and other COX-2-dependent metabolites. Transfec-
tion of cell lines with p23 expression vectors has been reported,
similar to loss of cPGES/p23, to result in inhibition of GR
activity in cells lines (16, 73). This raises the possibility that the
increased PGE2 production noted in cells transfected with
cPGES/p23 was the indirect consequence of decreased GR
function in this line.
Interestingly, the impact of loss of cPGES/p23 on prostanoid
production by fetal tissues was very different from that ob-
served with cultured cells. Here loss of this protein resulted in
decreased levels of PGE2 and other COX-dependent prostan-
oids. A number of possible explanations can be proposed.
First, the ability of GR to stimulate the production of prostan-
oids in specific cell types has been reported, particularly in
primary amniotic fibroblasts (15, 58, 78). These studies show
that dexamethasone increases expression of both cPLA2 and
COX-2 in these cells. Consistent with this finding, prenatal
dexamethasone increased prostaglandin synthesis in rat fetal
lung (64). Potential GREs have been defined in the COX-2
and cPLA2 promoters, which may play a role in the induction
of gene transcription (61, 75). It is interesting to speculate that,
in the mouse embryo, glucocorticoids, which increase in levels
as gestation progresses, contribute to the increase in prosta-
glandin production observed late in gestation. Alternatively,
the diminished prostanoid production might be the indirect
consequence of alterations in development of the cPGES/
p23/ embryos. Finally, the decreases in prostanoids in the
cPGES/p23/ mice may reflect an as-yet-unidentified GR-
independent function for cPGES/p23 in regulation of the ara-
chidonic acid pathway. For example, cPGES/p23 has been
shown to facilitate signaling of the aryl hydrocarbon receptor,
which in turn modulates the COX-2 pathway (10, 69). While
additional experiments will be necessary to address these ques-
tions, taken together, our data do not support the designation
of cPGES/p23 as the third PGE2 synthase, cPGES, and we
suggest that this protein simply be referred to as p23.
While the manuscript for this article was in preparation,
Grad et al. reported the generation of mice from the identical
ES cell clone carrying an insertional mutation in the cPGES/
p23 gene (19). A similar defect in lung and skin development
was noted, and cotransfection of a GR reporter construct and
a GR-expressing construct in fibroblasts derived from the em-
bryos demonstrated decreased GR-dependent transcription. In
contrast to the results shown here, the growth retardation of
the pups and decreased proliferation in the primary fibroblasts
were not noted in these studies. We also have reported the
defective induction of gluconeogenic enzymes and decreased
glycogen accumulation in the fetal livers. In addition, we have
shown that the ability of GR to regulate the activity of other
transcription factors, namely AP-1, is dependent on expression
of p23. These deficiencies, as well as decreased expression of
genes involved in lung development, suggest a role for p23 in
both the DNA-binding-dependent and -independent mecha-
nisms of GR. Finally, our analysis of prostanoids in the p23-
deficient animals and primary fibroblasts failed to support a
role for this protein as a PGE2 synthase.
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